Trial
NCT02782182
Perioperative FOLFIRINOX for Patients With Resectable Pancreatic Adenocarcinoma: A Pilot Study
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Chicago
Collaborators
—
Condition
Pancreatic Ductal Adenocarcinoma (PDAC)
Intervention
FOLFIRINOX (oxaliplatin, leucovorin, irinotecan)
Why stopped
Closed early due to poor accrual.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-03-19